<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">32923467</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2297-1769</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>7</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in veterinary science</Title>
          <ISOAbbreviation>Front Vet Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gonadotropin-Releasing Hormone (GnRH) Agonist Implants for Male Dog Fertility Suppression: A Review of Mode of Action, Efficacy, Safety, and Uses.</ArticleTitle>
        <Pagination>
          <StartPage>483</StartPage>
          <MedlinePgn>483</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">483</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fvets.2020.00483</ELocationID>
        <Abstract>
          <AbstractText>At present, only surgical sterilization is available for veterinarians and pet owners seeking suppression of fertility in male dogs, in most countries. An alternative contraceptive alternative approach is GnRH releasing implants that desensitize the pituitary to the stimulatory effects of GnRH and thereby block testicular function (testosterone and sperm production). Two GnRH agonists (deslorelin and azagly-nafarelin) have been researched in controlled release formulations for this purpose. A deslorelin-releasing biodegradable implant, marketed under the name Suprelorin®, has been available in Australia and New Zealand since 2007, the European Union (EU) since 2008, and received regulatory approval in China and Mexico in late 2019. Two versions of the implant are available, one labeled for a minimum of 6 months of fertility suppression in male dogs, and the other for a minimum of 12 months in male dogs. Another GnRH agonist (azagly-nafarelin) was also included in a solid implant (Gonazon®). Research results showed it delivered 6-months to 1 year of suppressed fertility; however, it is not commercialized. This review paper summarizes research on the mechanism of action for these technologies and compiles and interprets the research on efficacy and safety. New findings on usage of the deslorelin releasing implant in countries where veterinarians and pet owners have this option is shared. Research on off-label use of the product in male dogs is also reviewed. This review aims to aid in the evaluation of the deslorelin releasing implant as an adjunct or alternative for surgical sterilization of male dogs.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Driancourt and Briggs.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Driancourt</LastName>
            <ForeName>Marc Antoine</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Astek Consulting, Chateauneuf, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Briggs</LastName>
            <ForeName>Joyce R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Alliance for Contraception in Cats and Dogs, Portland, OR, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Vet Sci</MedlineTA>
        <NlmUniqueID>101666658</NlmUniqueID>
        <ISSNLinking>2297-1769</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">castrate</Keyword>
        <Keyword MajorTopicYN="N">chemical castration</Keyword>
        <Keyword MajorTopicYN="N">contracept</Keyword>
        <Keyword MajorTopicYN="N">fertility control</Keyword>
        <Keyword MajorTopicYN="N">male dog</Keyword>
        <Keyword MajorTopicYN="N">neuter</Keyword>
        <Keyword MajorTopicYN="N">non-surgical</Keyword>
        <Keyword MajorTopicYN="N">sterilize</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32923467</ArticleId>
        <ArticleId IdType="pmc">PMC7456901</ArticleId>
        <ArticleId IdType="doi">10.3389/fvets.2020.00483</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alliance for Contraception in Cats and Dogs (ACC&amp;D) 
Product Profile and Position Statement, Zeuterin/EsterilSol. (2016). Available online at: https://acc-d.org/docs/default-source/Resource-Library-Docs/pppp-zeuterinesterilsol-revised-may-2016.pdf?sfvrsn=2 (accessed May 06, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Alliance for Contraception in Cats and Dogs (ACC&amp;D) 
Calcium Chloride as a Non-Surgical Sterilant for Male Dogs and Cats: A History and Summary of Research. (2014). Available online at: https://www.acc-d.org/docs/default-source/Research-and-Innovation/accd_cacl2review-nov2014.pdf?sfvrsn=2 (accessed May 08, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Driancourt MA, Rhodes L.
Male contraception in animal species. In: Skinner MK, editor. Encyclopedia of Reproduction. Vol. 1
Cambridge, MA: Academic Press;  (2018). p. 553–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Y, Tian Y, Jiang S, Li F, Zhang Y, Zhang X, et al. . Immunization of dogs with recombinant GnRH-I suppresses the development of reproductive function. Theriogenology. (2015) 83:314–9. 10.1016/j.theriogenology.2014.06.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2014.06.029</ArticleId>
            <ArticleId IdType="pubmed">25468551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabeur K, Ball BA, Nett TM, Ball HH, Liu IKM. Effect of GnRH conjugated to pokeweed antiviral protein on reproductive function in adult male dogs. Reproduction. (2003) 125:801–6. 10.1530/rep.0.1250801</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/rep.0.1250801</ArticleId>
            <ArticleId IdType="pubmed">12773102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia Romero G, Valiente C, Aquilano D, Corrada Y, Gobello C. Endocrine effects of the GnRh antagonist, acyline, in domestic dogs. Theriogenology. (2009) 71:1234–7. 10.1016/j.theriogenology.2008.12.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2008.12.017</ArticleId>
            <ArticleId IdType="pubmed">19193431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA) 
Summary of Opinion (for Suprelorin 9.4mg Implant). (2010). Available online at: https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suprelorin__en.pdf (accessed December 12, 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA) 
Suprelorin: European Public Assessment Report – Summary for the Public. (2007). Available online at: https://www.ema.europa.eu/en/documents/overview/suprelorin-epar-summary-public__en.pdf (accessed December 12, 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Australian Pesticides and Veterinary Medicine (APVMA) 
Suprelorin12. Australian Pesticides and Veterinary Medicine Authority (APVMA) (2019). Available online at: http://websvr.infopest.com.au/LabelRouter?LabelType=LandMode=1andProductCode=60359 (accessed January 20, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>FDA 
New Treatment Helps Control Adrenal Gland Cortical Disease in Ferrets with a Dissolvable Implant, Announcement. (2012). Available online at: https://us.virbac.com/home/resources/news/pagecontent/latest-announcements/introduces-suprelorin-f-implant.html (accessed December 12, 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA) 
Suprelorin 4.7mg European Public Assessment Report – Product Information; Annex 1, Summary of Product Characteristics. (2008). Available online at: https://www.ema.europa.eu/en/documents/product-information/suprelorin-epar-product-information__en.pdf (accessed December 12, 2019)</Citation>
        </Reference>
        <Reference>
          <Citation>Ludwig C, Desmoulins PO, Driancourt MA, Goericke-Pesch S, Hoffmann B. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant Gonazon: a preclinical trial. Theriogenology. (2009) 71:1037–45. 10.1016/j.theriogenology.2008.10.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2008.10.015</ArticleId>
            <ArticleId IdType="pubmed">19233456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goericke-Pesch S, Wilhelm E, Ludwig C, Desmoulins P, Driancourt MA, Hoffman B. Evaluation of the clinical efficacy of Gonazon implants in the treatment of reproductive pathologies, behavioral problems, and suppression of reproductive function in the male dog. Theriogenology. (2010) 73:920–36. 10.1016/j.theriogenology.2009.11.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2009.11.018</ArticleId>
            <ArticleId IdType="pubmed">20097413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trigg TE, Doyle AG, Walsh JD, Swangchan-Uthai T. A review of the advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology. (2006) 66:1507–12. 10.1016/j.theriogenology.2006.02.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2006.02.037</ArticleId>
            <ArticleId IdType="pubmed">16600356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vickery BH, McRae GI, Goodpasture JC, Sanders LM. Use of potent LHRH analogues for chronic contraception and pregnancy termination in dogs. J Reprod Fert. (1989) 39:175–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2533612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padula AM. GnRH analogues- agonists and antagonists. Anim Reproduct Sci. (2005) 88:115–26. 10.1016/j.anireprosci.2005.05.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anireprosci.2005.05.005</ArticleId>
            <ArticleId IdType="pubmed">15955640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navarro C, Schober PA.
Pharmacodynamics and pharmacokinetics of a sustained-release implant of deslorelin in companion animals. In: 7th ISCFR 2012. Whistler, BC:  (2012). p. 177–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Trigg TE, Wright PJ, Armour AF, Williamson PE, Junaidi A, Martin GB, et al. . Use of a GnRH analogue implant to produce reversible longterm suppression of reproductive function in male and female domestic dogs. J Reprod Fertil Suppl. (2001) 57:255–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11787159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Junaidi A, Williamson PE, Cummins JM, Martin GB, Blackberry MA, Trigg TE. Use of a new drug delivery formulation of the gonadotrophin-releasing hormone analogue Deslorelin for reversible long-term contraception in male dogs. Reprod Fertil Dev. (2003) 15:317–22. 10.1071/RD03039</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1071/RD03039</ArticleId>
            <ArticleId IdType="pubmed">14975229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Junaidi A, Williamson PE, Martin GB, Blackberry MA, Cummins JM, Trigg TE. Dose-response studies for pituitary and testicular function in male dogs treated with the GnRH superagonist, Deslorelin. Reprod Domestic Anim. (2009) 44:725–34. 10.1111/j.1439-0531.2008.01060.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1439-0531.2008.01060.x</ArticleId>
            <ArticleId IdType="pubmed">19769638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romagnoli S, Siminica A, Sontas BH, Milani C, Mollo A, Steletta C. Semen quality and onset of sterility following administration of a 4.7-mg deslorelin implant in adult male dogs. Reprod Dom Anim. (2012) 47:389–92. 10.1111/rda.12058</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/rda.12058</ArticleId>
            <ArticleId IdType="pubmed">23279546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Gier J, Kooistra HS, Vinke CM.
The effects of orchiectomy and chemical castration using deslorelin on male dog behavior. Proceeding of EVSSAR Congress. Toulouse (2013). (Abstract).</Citation>
        </Reference>
        <Reference>
          <Citation>Junaidi A, Williamson PE, Trigg TE, Cummins JM, Martin GB. Morphological study of the effects of the GnRH superagonist deslorelin on the canine testis and prostate gland. Reprod Domestic Anim. (2009) 44:757–63. 10.1111/j.1439-0531.2008.01066.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1439-0531.2008.01066.x</ArticleId>
            <ArticleId IdType="pubmed">21815286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scientific—European Medicines Agency (EMA) 
Suprelorin, Scientific Discussion. (2007). Available online at: https://www.ema.europa.eu/en/documents/scientific-discussion/suprelorin-epar-scientific-discussion__en.pdf (accessed December 12, 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Polisca A, Orlandi R, Troisi A, Brecchia G, Zerani M, Boiti C, et al. . Clinical efficacy of the GnRH agonist (Deslorelin) in dogs affected by benign prostatic hyperplasia and evaluation of prostatic blood flow by Doppler ultrasound. Reprod Domest Anim. (2013) 48:673–80. 10.1111/rda</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/rda</ArticleId>
            <ArticleId IdType="pubmed">23320475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olson PN, Root Kustritz MV, Johnston SD. Early-age neutering of dogs and cats in the United States: a review. J Reprod Fert. (2001) 57:223–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11787153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orr B, Jones B. A survey of veterinarian attitudes toward prepubertal desexing of dogs and cats in the australian capital territory. Front Vet Med. (2019) 6:272. 10.3389/fvets.2019.00272</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fvets.2019.00272</ArticleId>
            <ArticleId IdType="pmc">PMC6712071</ArticleId>
            <ArticleId IdType="pubmed">31497606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Looney A, Bohling M, Bushby P, Howe L, Griffin B, Levy J, et al. . The Association of Shelter Veterinarians veterinary medical care guidelines for spay-neuter programs. J Am Vet Med Assoc. (2008) 233:74–86. 10.2460/javma.233.1.74</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2460/javma.233.1.74</ArticleId>
            <ArticleId IdType="pubmed">18593314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sirivaidyapong S, Mehl NS, Trigg TE. Delay of puberty and reproductive performance in male dogs following the implantation of 4.7 and 9.4 mg GnRH-agonist deslorelin at an early pre-pubertal age. Reprod Domest Anim. (2012) 47:400–2. 10.1111/rda.12066</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/rda.12066</ArticleId>
            <ArticleId IdType="pubmed">23279549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaya D, Shafer-Somi S, Kurt B, Kuru M, Kaya S, Kaçar C, et al. . Clinical use of deslorelin implants for the long term contraception in prepubertal bitches: effects on epiphyseal closure, body development and time to puberty. Theriogenology. (2015) 83:1147–53. 10.1016/j.theriogenology.2014.12.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2014.12.015</ArticleId>
            <ArticleId IdType="pubmed">25619808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart B, Eckstein R.
The role of gonadal hormones in the occurrence of objectionable behaviours in dogs and cats. Appl Anim Behav Sci. (1997) 52:331–44. 10.1016/S0168-1591(96)01133-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0168-1591(96)01133-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goericke Pesch S. Long-term effects of GnRH agonists on fertility and behaviour. Reprod Dom Anim. (2017) 52:336–47. 10.1111/rda.12898</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/rda.12898</ArticleId>
            <ArticleId IdType="pubmed">28025851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantziaras G, Alonge S, Faustini M, Luvoni GC. Assessment of the age for a preventive ultrasonographic examination of the prostate in the dog. Theriogenology. (2017) 100:114–9. 10.1016/j.theriogenology.2017.06.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2017.06.010</ArticleId>
            <ArticleId IdType="pubmed">28708525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Limmanont C, Phavaphutanon J, Sirinarumitr K.
Effect of finasteride and deslorelin treatment on clinical signs, prostatic volume and semen quality in dogs with benign prostatic hypertrophy: a clinical trial. Kasetsart J. (2012) 46:724–35.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin LJM, Silliart B, Duman HJW, Nguyen PG. Hormonal disturbances associated with obesity in dogs. J Anim Physiol Anim Nutr. (2006) 90:355–60. 10.1111/j.1439-0396.2005.00589.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1439-0396.2005.00589.x</ArticleId>
            <ArticleId IdType="pubmed">16958791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kustritz MVR. Determining the optimal age for gonadectomy of dogs and cats. J Am Vet Med Assoc. (2007) 231:1665–75. 10.2460/javma.231.11.1665</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2460/javma.231.11.1665</ArticleId>
            <ArticleId IdType="pubmed">18052800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefebvre SL, Yang M, Wang M, Elliott DA, Buff PR, Lund EM. Effect of age at gonadectomy on the probability of dogs becoming overweight. J Am Vet Med Assoc. (2013) 243:236–43. 10.2460/javma.243.2.236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2460/javma.243.2.236</ArticleId>
            <ArticleId IdType="pubmed">23822081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberbauer AM, Belanger JM, Famula TR. A review of the impact of neuter status on expression of inherited conditions in dogs. Front Vet Sci. (2019) 6:397. 10.3389/fvets.2019.00397</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fvets.2019.00397</ArticleId>
            <ArticleId IdType="pmc">PMC6863800</ArticleId>
            <ArticleId IdType="pubmed">31799281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jurczak A, Domosławska A, Janowski T, Zdu Czyk S.
Treatment of benign prostatic hyperplasia (BPH) in dogs using GnRH agonist implant Suprelorin®- preliminary results. Europ. Vet. Soc. Small Anim. Reprod. (2010) 118.</Citation>
        </Reference>
        <Reference>
          <Citation>Rubion S, Desmoulins PO, Riviere-Godet E, Kinziger M, Salavert F, Rutten F, et al. . Treatment with a subcutaneous GnRH agonist containing controlled release device reversibly prevents puberty in bitches. Theriogenology. (2006) 66:1651–4. 10.1016/j.theriogenology.2006.02.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2006.02.015</ArticleId>
            <ArticleId IdType="pubmed">16564080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grüntzig K, Graf R, Boo G, Guscetti F, Hässig M, Axhausen KW, et al. . Swiss canine cancer registry 1955–2008: occurrence of the most common tumour diagnoses and influence of age, breed, body size, sex and neutering status on tumour development. J Compar Pathol. (2016) 155:156–70. 10.1016/j.jcpa.2016.05.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcpa.2016.05.011</ArticleId>
            <ArticleId IdType="pubmed">27406312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ettinger M, Gust S, Kutzler M. Luteinizing hormone receptor expression by nonneoplastic and neoplastic canine lymphocytes. Am J Vet Res. (2019) 80:572–7. 10.2460/ajvr.80.6.572</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2460/ajvr.80.6.572</ArticleId>
            <ArticleId IdType="pubmed">31140843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kustritz MVR, Slater MR, Weedon GR, Bushby PA.
Determining optimal age for gonadectomy in the dog: a critical review of the literature to guide decision making. Med Acces Dec. (2017) 9:167–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Ortega-Pacheco A, Rodriguez-Buenfil JC, Bolio-Gonzalez ME, Sauri-Arceo CH, Jiménez-Coello M, Forsberg CL.
A survey of dog populations in urban and rural areas of Yucatan, Mexico. Anthrozoös. (2007) 20:261–74. 10.2752/089279307X224809</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2752/089279307X224809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poss JE, Bader JO. Results of a free Spay/Neuter program in a hispanic Colonia on the Texas-Mexico Border. J Appl Anim Welfare Sci. (2008) 11:346–51. 10.1080/10888700802330010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10888700802330010</ArticleId>
            <ArticleId IdType="pubmed">18821403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trevejo R, Yang M, Lund EM. Epidemiology of surgical castration of dogs and cats in the United States. J Am Vet Med Assoc. (2011) 238:898–904. 10.2460/javma.238.7.898</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2460/javma.238.7.898</ArticleId>
            <ArticleId IdType="pubmed">21453178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Downes MJ, Devitt C, Downes MT, More SJ. Neutering of cats and dogs in Ireland; pet owner self-reported perceptions of enabling and disabling factors in the decision to neuter. PeerJ. (2015) 3:e1196. 10.7717/peerj.1196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7717/peerj.1196</ArticleId>
            <ArticleId IdType="pmc">PMC4548501</ArticleId>
            <ArticleId IdType="pubmed">26312187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White SC, Scarlett JM, Levy J. Characteristics of clients and animals served by high-volume, stationary, nonprofit spay-neuter clinics. J Am Vet Med Assoc. (2018) 253:737–45. 10.2460/javma.253.6.737</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2460/javma.253.6.737</ArticleId>
            <ArticleId IdType="pubmed">30179099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wongsaengchan C, McKeegan DEF. The views of the UK public towards routine neutering of dogs and cats. Animals. (2019) 9:138. 10.3390/ani9040138</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ani9040138</ArticleId>
            <ArticleId IdType="pmc">PMC6523704</ArticleId>
            <ArticleId IdType="pubmed">30986979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BN Research—ACC&amp;D Non-Surgical Sterilization Study Veterinarian Attitude Awareness Survey November 2007.  (2007). Available online at: https://www.acc-d.org/docs/default-source/Research-and-Innovation/vetreport.pdf (accessed January 2, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>BN Research—ACC&amp;D Online Survey with Shelter Veterinarians Non-Surgical Alternatives to Spaying and Neutering.  (2007). Available online at: https://www.acc-d.org/docs/default-source/Research-and-Innovation/asvreport.pdf (accessed January 2, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Sontas BH, Kaysigiz F, Ekici H.
Methods of oestrus prevention in dogs and cats: a survey of Turkish veterinarians' practices and beliefs. Arch Med Vet. (2012) 44:155–66. 10.4067/S0301-732X2012000200009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4067/S0301-732X2012000200009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams V, Walker S, Taylor C.
Attitudes to and opinions of neutering in dogs: results of a canine reproduction survey of veterinary surgeons. Br Small Anim Vet Assoc Congr Proc. (2016) 475–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Moldave C, Lachaud MP.
A tail/tale of two products. In: 6th International Symposium on Non-Surgical Methods of Fertility Control. Boston, MA: Alliance for Contraception in Cats and Dogs;  (2018). Available online at: https://www.acc-d.org/docs/default-source/6th-symposium-proceedings/moldave-lachaud-accd-symposium-ppt.pdf (accessed May 06, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Spain CV, Scarlett JM, Houpt KA. Long-term risks and benefits of early-age gonadectomy in dogs. J Am Vet Med Assoc. (2004) 224:380–7. 10.2460/javma.2004.224.380</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2460/javma.2004.224.380</ArticleId>
            <ArticleId IdType="pubmed">14765797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer C, Corr S, Sandøe P.
Inconvenient desires: should we routinely neuter companion animals?
Anthrozoos. (2012) 25(Suppl): S153–72. 10.2752/175303712X13353430377255</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2752/175303712X13353430377255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albright S.
An Update on the Health Effects of Spay/Neuter in Dogs. American Kennel Club Canine Health Foundation (2019). Available online at: https://www.akcchf.org/educational-resources/library/articles/an-update-on-the-health.html (accessed 5/11/2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Alliance for Contraception in Cats and Dogs (ACC&amp;D) 
Results of Veterinary Survey Regarding Use of Suprelorin® (2018). Available online at: http://acc-d.org/docs/default-source/suprelorin-survey/suprelorin-survey-results.pdf (accessed on January 20, 2020).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
